Cancer of the gastroesophageal junction: Combined modality therapy

被引:16
作者
Ilson, David H.
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Med, Gastrointestinal Oncol Serv, New York, NY 10021 USA
[2] Weill Cornell Univ Med Coll, New York, NY 10021 USA
关键词
D O I
10.1016/j.soc.2006.07.011
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Esophageal cancer, an uncommon, but highly virulent, malignancy in the United States, will be responsible for nearly 14,000 deaths in the year 2005. The prognosis for patients who have adenocarcinoma of the distal esophagus and gastroesophageal junction and who are treated with the standard approaches of surgery or combined chemoradiation therapy is poor. Recent clinical trials have evaluated the use of preoperative chemotherapy followed by surgery, combined concurrent preoperative chemoradiotherapy followed by surgery, or definitive chemoradiotherapy alone without surgery. This article focuses on recent advances in the use of combined modality therapy in adenocarcinoma of the esophagus and gastroesophageal junction.
引用
收藏
页码:803 / +
页数:23
相关论文
共 89 条
[31]  
Govindan R, 2004, J CLIN ONCOL, V22, p326S
[32]  
Harpole DH, 2001, CLIN CANCER RES, V7, P562
[33]   Timeline - Gefitinib - a novel targeted approach to treating cancer [J].
Herbst, RS ;
Fukuoka, M ;
Baselga, J .
NATURE REVIEWS CANCER, 2004, 4 (12) :956-965
[34]   COMBINED CHEMOTHERAPY AND RADIOTHERAPY COMPARED WITH RADIOTHERAPY ALONE IN PATIENTS WITH CANCER OF THE ESOPHAGUS [J].
HERSKOVIC, A ;
MARTZ, K ;
ALSARRAF, M ;
LEICHMAN, L ;
BRINDLE, J ;
VAITKEVICIUS, V ;
COOPER, J ;
BYHARDT, R ;
DAVIS, L ;
EMAMI, B .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 326 (24) :1593-1598
[35]  
HICKEY K, 1994, CANCER, V74, P1693, DOI 10.1002/1097-0142(19940915)74:6<1693::AID-CNCR2820740609>3.0.CO
[36]  
2-#
[37]  
Hirai T, 1998, Dis Esophagus, V11, P221
[38]   Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus [J].
Hulscher, JBF ;
van Sandick, JW ;
de Boer, AGEM ;
Wijnhoven, BPL ;
Tijssen, JGP ;
Fockens, P ;
Stalmeier, PFM ;
ten Kate, FJW ;
van Dekken, H ;
Obertop, H ;
Tilanus, HW ;
van Lanschot, JJB .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (21) :1662-1669
[39]   Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer [J].
Hurwitz, H ;
Fehrenbacher, L ;
Novotny, W ;
Cartwright, T ;
Hainsworth, J ;
Heim, W ;
Berlin, J ;
Baron, A ;
Griffing, S ;
Holmgren, E ;
Ferrara, N ;
Fyfe, G ;
Rogers, B ;
Ross, R ;
Kabbinavar, F .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) :2335-2342
[40]   Phase I trial of escalating-dose irinotecan given weekly with cisplatin and concurrent radiotherapy in locally advanced esophageal cancer [J].
Ilson, DH ;
Bains, M ;
Kelsen, DP ;
O'Reilly, E ;
Karpeh, M ;
Coit, D ;
Rusch, V ;
Gonen, M ;
Wilson, K ;
Minsky, BD .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (15) :2926-2932